About: Saroglitazar

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Saroglitazar (INN, trade name Lipaglyn) is a drug for the treatment of type 2 diabetes mellitus and dyslipidemia. It is approved for use in India by the Drug Controller General of India. Saroglitazar is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). It has also shown anti-diabetic medication properties by reducing the fasting plasma glucose and HBA1c in diabetes patients.

Property	Value
dbo:abstract	Saroglitazar (INN, trade name Lipaglyn) is a drug for the treatment of type 2 diabetes mellitus and dyslipidemia. It is approved for use in India by the Drug Controller General of India. Saroglitazar is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). It has also shown anti-diabetic medication properties by reducing the fasting plasma glucose and HBA1c in diabetes patients. (en)
dbo:alternativeName	Lipaglyn (en)
dbo:casNumber	495399-09-2
dbo:chEBI	134708
dbo:fdaUniiCode	E0YMX3S4JD
dbo:pubchem	60151560
dbo:thumbnail	wiki-commons:Special:FilePath/Saroglitazar_skeletal.svg?width=300
dbo:wikiPageID	39596242 (xsd:integer)
dbo:wikiPageLength	6274 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1122994566 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Hypertriglyceridemia dbr:Dyslipidemia dbr:Insulin_resistance dbr:PPAR_agonist dbc:Carboxylic_acids dbr:Anti-diabetic_medication dbr:Statin dbr:Triglycerides dbr:Drug_Controller_General_of_India dbr:Diabetic_nephropathy dbr:HDL_cholesterol dbr:International_Nonproprietary_Name dbr:Cholesterol dbc:PPAR_agonists dbr:Peroxisome_proliferator-activated_receptor dbr:Retinopathy dbr:PPARα dbr:PPARγ dbr:HbA1c dbr:Insulin_sensitizer dbr:Type_2_diabetes_mellitus
dbp:atcPrefix	None (en)
dbp:c	25 (xsd:integer)
dbp:casNumber	495399 (xsd:integer)
dbp:chebi	134708 (xsd:integer)
dbp:chemspiderid	32079086 (xsd:integer)
dbp:h	29 (xsd:integer)
dbp:iupacName	-2 (xsd:integer)
dbp:legalStatus	Approved in India (en)
dbp:n	1 (xsd:integer)
dbp:o	4 (xsd:integer)
dbp:pregnancyCategory	C (en)
dbp:pubchem	60151560 (xsd:integer)
dbp:routesOfAdministration	Oral (en)
dbp:s	1 (xsd:integer)
dbp:smiles	CSc3ccc-cn1CCOcccc2CCOCC (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	MRWFZSLZNUJVQW-DEOSSOPVSA-N (en)
dbp:tradename	Lipaglyn (en)
dbp:unii	E0YMX3S4JD (en)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:PPAR_modulators dbt:Reflist dbt:Short_description dbt:Fdacite dbt:Oral_hypoglycemics_and_insulin_analogs
dcterms:subject	dbc:Carboxylic_acids dbc:PPAR_agonists
gold:hypernym	dbr:Drug
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatCarboxylicAcids yago:WikicatMolecularFormulas yago:Abstraction100002137 yago:Acid114607521 yago:CarboxylicAcid114739360 yago:Chemical114806838 yago:Communication100033020 yago:Compound114818238 yago:Formula106816935 yago:Material114580897 yago:Matter100020827 yago:Message106598915 yago:MolecularFormula106817173 yago:Part113809207 yago:PhysicalEntity100001930 yago:Relation100031921 dbo:Drug yago:Statement106722453 yago:Substance100019613
rdfs:comment	Saroglitazar (INN, trade name Lipaglyn) is a drug for the treatment of type 2 diabetes mellitus and dyslipidemia. It is approved for use in India by the Drug Controller General of India. Saroglitazar is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). It has also shown anti-diabetic medication properties by reducing the fasting plasma glucose and HBA1c in diabetes patients. (en)
rdfs:label	Saroglitazar (en)
owl:sameAs	freebase:Saroglitazar yago-res:Saroglitazar wikidata:Saroglitazar dbpedia-sh:Saroglitazar dbpedia-sr:Saroglitazar https://global.dbpedia.org/id/XApf
prov:wasDerivedFrom	wikipedia-en:Saroglitazar?oldid=1122994566&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Saroglitazar_skeletal.svg
foaf:isPrimaryTopicOf	wikipedia-en:Saroglitazar
is dbo:wikiPageRedirects of	dbr:C25H29NO4S dbr:Lipaglyn
is dbo:wikiPageWikiLink of	dbr:PPAR_agonist dbr:C25H29NO4S dbr:Lipaglyn
is foaf:primaryTopic of	wikipedia-en:Saroglitazar